-
Mashup Score: 35Parkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel - 11 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 30
Multiple Myeloma (MM) remains a challenging hematological malignancy despite significant advancements made during the past 2 decades. Outcomes have improved by incorporating immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies into treatment algorithms that include high dose chemotherapy and autologous hematopoietic stem cell transplantation. However, many patients may eventually relapse despite these innovations. Newer therapies targeting B-Cell Maturation Antigen (BCMA) offer promise for patients with relapsed or refractory disease.
Categories: General Medicine News, Hem/OncsTweet-
Check our recent review article: Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma #mmsm @UAMSMyeloma ➡️ https://t.co/2fGJKx5oK6 https://t.co/DxWMYRK1Bq
-
-
Mashup Score: 59Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab - 11 month(s) ago
eJHaem is a Gold open access haematology journal of the British Society for Haematology, publishing practice and research papers applicable to a worldwide readership.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Check our recent paper: Weight loss and dysgeusia in relapsed/refractory MM patients treated with talquetamab #mmsm ➡️ https://t.co/JpaXzvtXWb ✅Dysgeusia persisted in 15% of pts ✅pts lost 6% of their weight during ttt, weight loss persisted in~half of pts post-discontinuation https://t.co/lfe5F5Nfj9
-
-
Mashup Score: 12Letter to the Editor: Chair of ABIM Hematology Board Advocates for MOC Assessment | ASH Clinical News | American Society of Hematology - 12 month(s) ago
In this Letter to the Editor, Morie Getz, MD, MACP, chair of the American Board of Internal Medicine’s (ABIM) Hematology Board, chair emeritus of the Department of Medicine at Mayo Clinic, and a member of the American Society of Hematology (ASH), responds to a letter written by Robert Brodsky, MD, 2023 ASH president and director of hematology at Johns Hopkins University. Dr. Brodsky’s letter, written in September 2023, was addressed to Richard Baron, MD, MACP, president and chief executive officer of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Chair of ABIM Hematology Board Advocates for MOC Assessment @ASHClinicalNews @ASH_hematology @MorieGertz @ABIMFoundation I encourage all to read those points clarifying many inaccuracies & categorically rejecting all counterarguments ➡️ https://t.co/ymBva8teXA
-
-
Mashup Score: 12Letter to the Editor: Chair of ABIM Hematology Board Advocates for MOC Assessment | ASH Clinical News | American Society of Hematology - 12 month(s) ago
In this Letter to the Editor, Morie Getz, MD, MACP, chair of the American Board of Internal Medicine’s (ABIM) Hematology Board, chair emeritus of the Department of Medicine at Mayo Clinic, and a member of the American Society of Hematology (ASH), responds to a letter written by Robert Brodsky, MD, 2023 ASH president and director of hematology at Johns Hopkins University. Dr. Brodsky’s letter, written in September 2023, was addressed to Richard Baron, MD, MACP, president and chief executive officer of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Chair of ABIM Hematology Board Advocates for MOC Assessment @ASHClinicalNews @ASH_hematology @MorieGertz @ABIMFoundation I encourage all to read those points clarifying many inaccuracies & categorically rejecting all counterarguments ➡️ https://t.co/ymBva8teXA
-
-
Mashup Score: 5
The long-term follow-up results of CASSIOPEIA show that including daratumumab in both the induction and consolidation phase and the maintenance phase led to superior progression-free survival outcomes. Our results confirm D-VTd induction and consolidation as a standard of care, and support the option of subsequent daratumumab monotherapy maintenance, for transplant-eligible patients with newly diagnosed multiple myeloma.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Some important messages from CASSIOPEIA trial #mmsm @TheLancetOncol #EHA24 ➡️ https://t.co/WFc4qbusiO ✅median follow-up: ~6-7 years from first and second randomization 🧵 https://t.co/r59KdHC9MR
-
-
Mashup Score: 1Samer Al Hadidi on academic moderation - OncoDaily - 12 month(s) ago
Samer Al Hadidi on academic moderation / academic institutions, academic moderation, academic productivity, cancer, medical oncology, OncoDaily, Oncology,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Samer Al Hadidi on academic moderation @HadidiSamer @UAMSMyeloma @UMich https://t.co/2DNLKdlG6z #AcademicInstitutions #A…
-
-
Mashup Score: 37Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review - 12 month(s) ago
AbstractBackground. Subgroup analyses in clinical trials assess intervention effects on specific patient subgroups, ensuring generalizability. However, they are
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet-
Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review-final version Led by excellent 🇯🇴 students ➡️https://t.co/8li1jXjELd Increased use of post hoc subgroup analysis, with 85% not reporting the post hoc nature of their analysis👇 https://t.co/8Eww641J1T
-
-
Mashup Score: 2
The long-term follow-up results of CASSIOPEIA show that including daratumumab in both the induction and consolidation phase and the maintenance phase led to superior progression-free survival outcomes. Our results confirm D-VTd induction and consolidation as a standard of care, and support the option of subsequent daratumumab monotherapy maintenance, for transplant-eligible patients with newly diagnosed multiple myeloma.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Some important messages from CASSIOPEIA trial #mmsm @TheLancetOncol #EHA24 ➡️ https://t.co/WFc4qbusiO ✅median follow-up: ~6-7 years from first and second randomization 🧵 https://t.co/r59KdHC9MR
-
-
Mashup Score: 70Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies - 1 year(s) ago
In recent years, the therapeutic landscape for hematological malignancies has markedly advanced, particularly since the inaugural approval of autologous chimeric antigen receptor T cell (CAR-T) therapy in 2017 for relapsed/refractory acute lymphoblastic leukemia (ALL). Autologous CAR-T therapy involves the genetic modification of a patient’s T cells to specifically identify and attack cancer cells, while bispecific antibodies (BsAbs) function by binding to both cancer cells and immune cells simultaneously, thereby triggering an immune response against the tumor.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies @MolTherapy #mmsm #celltherapy #bmtsm #lymsm #leusm @UAMSMyeloma @CAGTHouston ➡️ https://t.co/qphlkATu7t Many figures and tables , check few 👇 https://t.co/hY1DcjM953
-
Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel #mmsm Nice summary tables of reported Parkinson-like neurotoxicity with BCMA CAR-T👇 ➡️ https://t.co/LBN1fztEGS Such rare AEs occur with Ide- cel as well as Cilta-cel -imp for informed consent https://t.co/FBNmKbtbsj